MPM kicks off a new I/O player with $44.5M round and a new understanding of the T cell receptor
After running in stealth mode for more than a year gaining better understanding of the complex structure of subunits involved in the T cell receptor, TCR² has now jumped into view in Cambridge, MA with a $44.5 million startup round and some big plans to make some original progress in immuno-oncology.
Garry Menzel, the former COO at Regulus, has taken charge as the new CEO. He’s teaming up with ex-Merck KGaA scientist Robert Hofmeister, who’s credited with a senior role in developing that company’s PD-L1 checkpoint, and Patrick Baeuerle, the former CSO at Micromet.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.